Table 2.
Carriership of rare CNVs affecting cardiovascular system development in the study samples. p-adj.: p-values (unadjusted) and OR (odds ratio) were calculated for a comparison between patients and all control subjects. 95% CI = 95% confidence interval. *) The CeAD samples included two families with two affected siblings, but only one sibling of each family was included in this analysis.
| CeAD Patients* | Ischemic Stroke Controls | Finnish Healthy Controls | German Healthy Controls |
All
Controls |
p-value | OR | 95% CI | |
|---|---|---|---|---|---|---|---|---|
| n=831 | n=565 | n=215 | n=1260 | n=2040 | ||||
| Carriership of rare CNVs | ||||||||
| CNVs affecting muscle organ development | 8 | 2 | 0 | 1 | 3 | 0.003 | 6.60 | 1.75-24.9 |
| CNVs affecting cell differentiation | 18 | 0 | 1 | 12 | 13 | <0.001 | 3.45 | 1.68-7.08 |
| CNVs affecting cardiovascular system development | 21 | 5 | 2 | 15 | 22 | 0.006 | 2.38 | 1.30-4.35 |